CB1 Receptor Antagonist Selonabant (ANEB‐001) Blocks Acute THC Effects in Healthy Volunteers: A Phase II Randomized Controlled Trial

Abstract Emergency department visits due to cannabinoid‐induced toxicity, including acute cannabinoid intoxication (ACI) have increased worldwide as more states have liberalized cannabis policy. ACI symptoms include anxiety, panic attacks, tachycardia, and psychosis, primarily mediated through cannabinoid type 1 receptor (CB1) agonism by Δ9‐tetrahydrocannabinol (THC). This phase II randomized, double‐blind, placebo‐controlled study assessed the potential of CB1 receptor antagonist selonabant (ANEB‐001) to block THC‐induced effects in healthy adults. In Part A of the study, 10.5 mg of THC was coadministered with